TR4 nuclear receptor alters the prostate cancer CD133+ stem/progenitor cell invasion via modulating the EZH2-related metastasis gene expression

Molecular Cancer Therapeutics

Volumn 14, Issue 6, 2015, Pages 1445-1453

  Zhu, Jin ^a,b   Yang, Dong Rong ^a,b   Sun, Yin ^b   Qiu, Xiaofu ^b,c   Chang, Hong Chiang ^b,d   Li, Gonghui ^b   Shan, Yuxi ^a,b   Chang, Chawnshang ^b,e  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CELL NUCLEUS RECEPTOR; GELATINASE B; NOTCH1 RECEPTOR; TESTICULAR NUCLEAR RECEPTOR 4; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; NR2C2 PROTEIN, HUMAN; PEPTIDE; POLYCOMB REPRESSIVE COMPLEX 2; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE; PROTEIN BINDING; STEROID RECEPTOR; THYROID HORMONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CANCER THERAPY; CELL INVASION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; CELL CULTURE; CELL MOTION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

AC133 ANTIGEN; ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MALE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PEPTIDES; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTOR, NOTCH1; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS;

EID: 84930957605     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0971     Document Type: Article

References (50)

1. Lang SH, Frame FM, Collins AT. Prostate cancer stem cells. J Pathol 2009;217:299-306.
2. Shyr C-R, Kang H-Y, Tsai M-Y, Liu N-C, Ku P-Y, Huang K-E, et al. Roles of testicular orphan nuclear receptors 2 and 4 in early embryonic development and embryonic stem cells. Endocrinology 2009;150:2454-62.
3. Collins LL, Lee Y-F, Ting H-J, Lin W-J, Liu N-C, Meshul CK, et al. The roles of testicular nuclear receptor 4 (TR4) in male fertility-priapism and sexual behavior defects in TR4 knockout mice. Reprod Biol Endocrinol 2011;9:138.
4. Lin S-J, Ho H-C, Lee Y-F, Liu N-C, Liu S, Li G, et al. Reduced osteoblast activity in the mice lacking TR4 nuclear receptor leads to osteoporosis. Reprod Biol Endocrinol 2012;10:43.
5. Lee Y-F, Liu S, Liu N-C, Wang R-S, Chen L-M, Lin W-J, et al. Premature aging with impaired oxidative stress defense in mice lacking TR4. Am J Physiol Endocrinol Metab 2011;301:E91-E8.
6. Lin S-J, Lee SO, Lee Y-F, Miyamoto H, Yang D-R, Li G, et al. TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system. Carcinogenesis 2014;35:1399-406.
7. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21-9.
8. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
9. Lee SO, Ma Z, Yeh C-R, Luo J, Lin T-H, Lai K-P, et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol 2013;5:14-26.
10. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67:3153-61.
11. Yang D-R, Ding X-F, Luo J, Shan Y-X, Wang R, Lin S-J, et al. Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer. J Biol Chem 2013;288:16476-83.
12. Xiang B, Muthuswamy SK. Using three-dimensional acinar structures for molecular and cell biological assays. Methods Enzymol 2006;406:692-701.
13. Carey MF, Peterson CL, Smale ST. Chromatin immunoprecipitation (ChIP). Cold Spring Harb Protoc 2009;2009: pdb. prot5279.
14. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008;26:2862-70.
15. Luo J, Ok Lee S, Liang L, Huang CK, Li L, Wen S, et al. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene 2014;33:2768-78.
16. Ding X, Yang D-R, Lee SO, Chen Y-L, Xia L-Q, Lin S-J, et al. TR4 nuclear receptor promotes prostate cancer metastasis via up-regulation of CCL2/CCR2 signaling. Int J Cancer 2015;136:955-64.
17. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.
18. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, De Marzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008;68:9703-11.
19. Reggiani Bonetti L, Migaldi M, Boninsegna A, Fanali C, Farina M. Expression of CD133 correlates with tumor stage, lymph node metastasis and recurrence in oral squamous cell carcinoma. J Cancer Sci Ther 2014;6:094-8.
20. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23.
21. Mehra N, Penning M, Maas J, Beerepoot LV, Van Daal N, Van Gils CH, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 2006;12:4859-66.
22. Eaton CL, Colombel M, Van Der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, et al. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010;70:875-82.
23. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.
24. Moore HM. The Role of EZH2 in Breast Cancer Progression and Metastasis. 2013;138:741-52.
25. Rao Z-Y, Cai M-Y, Yang G-F, He L-R, Mai S-J, Hua W-F, et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-b1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010;31:1576-83.
26. Shin YJ, Kim J-H. The role of EZH2 in the regulation of the activity ofmatrix metalloproteinases in prostate cancer cells. PLoS ONE 2012;7:e30393.
27. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
28. Xie S, Lee Y-F, Kim E, Chen L-M, Ni J, Fang L-Y, et al. TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc Natl Acad Sci 2009;106:13353-8.
29. Trerotola M, Rathore S, Goel HL, Li J, Alberti S, Piantelli M, et al. CD133, Trop-2 and alpha 2 beta 1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res 2010;2:135-44.
30. Simandi Z, Cuaranta-Monroy I, Nagy L. Nuclear receptors as regulators of stem cell and cancer stem cell metabolism. Semin Cell Dev Biol 2013;24:716-23.
31. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012;56:622-31.
32. Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 2011;17:12-20.
33. Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, Pylayeva-Gupta Y, et al. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 2012;26:439-44.
34. Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010;10:788-95.
35. Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Falth M, Sultmann H, et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 2011;6:e21651.
36. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011;17:2613-8.
37. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci 2012;109:21360-5.
38. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009;14:29-43.
39. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
40. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009;69:2887-95.
41. Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-tomesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers 2011;3:716-29.
42. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
43. Ouyang G, Wang Z, Fang X, Liu J, Yang CJ. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci 2010;67:2605-18.
44. Niu Y, Altuwaijri S, Lai K-P, Wu C-T, Ricke WA, Messing EM, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci 2008;105:12182-7.
45. Fan S, Wang J-A, Yuan R, Ma YX, Meng Q, Erdos MR, et al. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 1998;16:3069-82.
46. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011;41:210-20.
47. Kim E, Liu N-C, Yu I-C, Lin H-Y, Lee Y-F, Sparks JD, et al. Metformin inhibits nuclear receptor TR4-mediated hepatic stearoyl-CoA desaturase 1 gene expression with altered insulin sensitivity. Diabetes 2011;60:1493-503.
48. Sahra IB, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010;70:2465-75.
49. He X-X, Tu S, Lee M-H, Yeung S-C. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011;22:2640-5.
50. Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 2010;6:670-1.